Heat Biologics Inc. (NASDAQ:HTBX) has regained its listing on the Nasdaq Stock Market. This was confirmed through a letter from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. (“Nasdaq”). The company had complied with the $1.00 per share minimum closing bid price requirement and the Listing Rule 5550(a) (2).
This was an important step for the biopharmaceutical company, which is expanding its activities to accommodate the development of a COVID-19 vaccine. For many years, and through its gp96 platform, the company has been developing first-in-class therapies to stimulate immune responses against cancer.
Some of the company’s product candidates, which have gone through the platform, include HS-110 and HS-130. The two have completed their Phase 2 trial and Phase 1 trial enrollments, respectively. In addition to this, the company has a COVID-19 vaccine program in the preclinical development stage.
Signs of Early Success from the Company’s Covid-19 Vaccine
Just like hundreds of other companies across the globe, Heat has engaged in research for a vaccine for the current pandemic, COVID-19. According to CEO Jeff Wolf, the company is committed to helping in combating the spread of coronavirus.
The good news is that there is a significant milestone in the vaccine’s positive development and signs of success. The preclinical testing has demonstrated a possible expansion of human-HLA-restricted T-cells, thanks to the vaccine. This would be against the epitopes of the SARS-CoV-2 Spike protein. All this and the good results have been enhanced by using the gp96 platform alongside other systems.
Heat Has a Partnership with Wisconsin-based Waisman Biomanufacturing
Collaborations, partnerships, and acquisitions have proven to be an incredible way of attaining growth for many companies. For the last couple of months, Heat has been working with Waisman Biomanufacturing to produce a COVID-19 vaccine. The two are not only working on the coronavirus vaccine but several other tests.
Wold is confident about the vaccine, which he says best suits the elderly who are more vulnerable to the virus and those with underlying health conditions.
